ISBN: 9783540331766 - tumor angiogenesis: basic mechanisms and cancer therapy (18 Ergebnisse)

Zustand: Good. : Este libro profundiza en los mecanismos básicos de la angiogénesis tumoral y su terapia. Editado por Dieter Marmé y Norbert Fusenig, incluye referencias bibliográficas exhaustivas e índice. Cubre aspectos esenciales de la neovascularización y los inhibidores de la neovascularización, ofreciendo una visión detallada para profesionales e investigadores en el campo de la oncología. EAN: 9783540331766 Tipo: Libros Categoría: Ciencias|Salud y Bienestar Título: Tumor angiogenesis Autor: Dieter Marmé| Norbert Fusenig Editorial: Springer Idioma: en Páginas: 845 Formato: Tapa dura Año de publicación: 2007.…

Zustand: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Zustand: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Zustand: New. pp. 864.

Zustand: New. pp. 864 6:B&W 8.25 x 11 in or 280 x 210 mm Perfect Bound on White w/Gloss Lam.

Zustand: New. pp. 864.

Zustand: Sehr gut. Zustand: Sehr gut | Seiten: 864 | Sprache: Englisch | Produktart: Bücher | Preface Tumor development and progression occur as a result of cumulative acquisition of genetic alterations affecting oncogenes and tumor suppressor genes. As a consequence of these alterations the arising tumor gains some fatal properties such as increased cell proliferation and decreased apoptosis, resulting in a net accumulation of tra- formed cells. Once a critical volume is achieved, lack of oxygen and nutrients limits further growth. To overcome this obstacle, the tumor cells initiate a program focused on the formation of new blood vessels within the host tissue. This process is termed tumor angiogenesis and contributes to the progression of most solid tumors and the formation of metastases. Since its discovery more than 30 years ago by Dr. Judah Folkman, tumor angiog- esis has been proposed as an ideal target for novel tumor therapies. Today the first anti-angiogenic compounds are available for the treatment of patients but their s- cess in the clinic is rather limited when given as monotherapies. This is in contrast to many preclinical results which revealed a much higher efficacy of these therapeutics in appropriate animal models. The reasons for this discrepancy are manifold, one being the existence of more than one angiogenic signaling system capable of driving tumor angiogenesis. Therefore it is no surprise that the inhibition of just one system is not sufficient to block the formation of new blood vessels in patients.…

Zustand: New.

Zustand: As New. Unread book in perfect condition.

Brossura. Zustand: fine. Heidelberg, 2007; pp. 863. Libro.

Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Preface Tumor development and progression occur as a result of cumulative acquisition of genetic alterations affecting oncogenes and tumor suppressor genes. As a consequence of these alterations the arising tumor gains some fatal properties such as increased cell proliferation and decreased apoptosis, resulting in a net accumulation of tra- formed cells. Once a critical volume is achieved, lack of oxygen and nutrients limits further growth. To overcome this obstacle, the tumor cells initiate a program focused on the formation of new blood vessels within the host tissue. This process is termed tumor angiogenesis and contributes to the progression of most solid tumors and the formation of metastases. Since its discovery more than 30 years ago by Dr. Judah Folkman, tumor angiog- esis has been proposed as an ideal target for novel tumor therapies. Today the first anti-angiogenic compounds are available for the treatment of patients but their s- cess in the clinic is rather limited when given as monotherapies. This is in contrast to many preclinical results which revealed a much higher efficacy of these therapeutics in appropriate animal models. The reasons for this discrepancy are manifold, one being the existence of more than one angiogenic signaling system capable of driving tumor angiogenesis. Therefore it is no surprise that the inhibition of just one system is not sufficient to block the formation of new blood vessels in patients.…

Hardcover. Zustand: Brand New. 1st edition. 845 pages. 10.00x8.00x1.75 inches. In Stock.

Hardcover. Zustand: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

Gebunden. Zustand: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. With contributions by numerous experts|Written by internationally renowned expertsNo competitionDevelopment of novel drugs (e.g. Avastin) makes new therapeutic strategies in the treatment of cancer possibleWith contributions by nume.…

Buch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Tumor angiogenesis is one of the most prominent mechanisms driving tumor development and progression. This book is written by internationally renowned experts. Part 1 describes the basic mechanisms. Tumor-angiogenic signaling pathways are presented as new potential targets for anti-angiogenic therapy. Part 2 reviews the efforts made to validate new targets and to show efficacy in animals. Part 3 is devoted to the clinical development of the novel anti-angiogenic drugs and their use in clinical practice. 864 pp. Englisch. …

Buch. Zustand: Neu. This item is printed on demand - Print on Demand Titel. Neuware -This book is divided into 3 parts. Part 1 summarizes the pro-angiogenic factors and anti-angiogenic molecules including their mechanism of action. Part 2 summarizes the preclinical data arising from the experimental evaluation of anti-angiogenic and pro-angiogenic compounds in cell culture and animal models. This will help to elucidate their mechanism of action in different biologic systems and cancer types. Based on this knowledge, clinicians will be able to incorporate these new drugs into the scenario of established therapies and finally improve curative approaches. Part 3 summarizes experimental and clinical studies of combined therapy with anti-angiogenic agents and highlights the challenges related to the appropriate strategies for selection of the patients, study design, and choice of proper end points for preclinical and clinical studies using these agents.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 864 pp. Englisch.…